Phase 2 Clinical Trial Of Ibrutinib Shows High Overall Response,...

An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma continues to show unprecedented and durable results with few side effects.

http://www.medilexicon.com/medicalnews.php?newsid=254134